Navigation Links
Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
Date:4/26/2012

e sheet, we've recently completed a number of acquisitions to add to the Phase 2 developments in our pipeline, including an exciting hematology asset and a novel cell-based platform for our regenerative medicine business. We're very pleased with the progress of several other studies across our pipeline, particularly the positive Phase 2 clinical data for VYVANSE in the treatment of binge eating disorder released today.

We've made a strong start to the year and reiterate our expectation of good earnings growth in 2012."

FINANCIAL SUMMARY

First Quarter 2012 Unaudited Results

Q1 2012 Q1 2011 Non Non US GAAP Adjustments GAAP US GAAP Adjustments GAAP $M $M $M $M $M $M Total revenues 1,172 - 1,172 972 - 972 Operating income 295 67 362 267 39 306 Diluted earnings per ADS $1.24 $0.24 $1.48 $1.11 $0.12 $1.23

  • Product sales were up 24% to $1,107 million (Q1 2011: $889 million). The growth in product sales was driven particularly by VYVANSE® (up 29% to $260 million), REPLAGAL® (up 28% to $134 million), ELAPRASE® (up 21% to $126 million), VPRIV® (up 22% to $72 million), FIRAZYR® (up 272% to $20 million) and INTUNIV® (up 63% to $69 million). On a constant exchange rate ("CER") basis, which is a Non GAAP measure, product sales were up 26%.

    Q1 2012 also included $49 million of DERMAGRAFT® sales (Q1 2011: $nil). Excluding sales of DERMAGRAFT, which was acquired with Advanced BioHealing Inc. ("ABH") in Q2 2011, product sales were up 19%.
  • Total revenues were up 21%, to $1,172 million (Q1 2011: $972 million), as the growth in product sales was partially offset, as expected, by a lower level of royalties and other revenues.

  • On a Non GAAP basis, operating income was up 18% to $362 million (Q1 2011: $306 million) as to
    '/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... JUPITER, Fla. , Aug. 3, 2015 /PRNewswire/ ... announced initiation of its second clinical development program ... drug candidate, CL-H1T.  CL-H1T contains ... is being developed as a treatment for migraine ... "Many patients with migraine headaches ...
(Date:8/3/2015)... and FLORHAM PARK, N.J. , ... once-daily naldemedine met its primary and secondary endpoints in ... of opioid-induced constipation (OIC) in adult patients with chronic ... mu-opioid receptor antagonist (PAMORA). This is the third Phase ... key secondary endpoints. Study results showed that ...
(Date:8/3/2015)... ZIONA, Israel , August 3, 2015 /PRNewswire/ ... today announced it received the statistical analysis of results from ... administered in the BVX-005 phase II trial which took place ... which did not exist at the time of the study- ... that caused the epidemic in the United States ...
Breaking Medicine Technology:Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
(Date:8/3/2015)... ... August 03, 2015 , ... ... 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb B2B Awards ... brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics product was ...
(Date:8/3/2015)... ... 03, 2015 , ... To date, many pharmaceutical and biotech ... of benefits, allowing them to gain access to capabilities that cannot be found ... resources, get access to innovation and ensure timely introduction of product into the ...
(Date:8/3/2015)... ... August 03, 2015 , ... A recent survey by ... of Hispanics believe people can positively affect their diabetes, few look beyond diet ... making diet changes was important. Far fewer participants mentioned the need for exercise ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... and the largest online retailer of nutritional supplements, has officially opened the ... for 11 awards in the following categories:, ,     Brand ...
(Date:8/3/2015)... Venice Beach, CA (PRWEB) , ... August 03, ... ... supporting individuals suffering from ALS and amputation , AUGUST 3, 2015 – Since ... DIY category in March 2015, Not Impossible – an organization whose mission is ...
Breaking Medicine News(10 mins):Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4
... Kentucky Ranks 47th Nationwide in Health Status; Anthem Blue ... services to more than 5,000, Kentuckians located in ... LOUISVILLE, Ky., Nov. 14 Anthem Blue Cross and ... program that,incorporates public health data to identify and help ...
... in with a strong,70% Omega-3 fatty acid content, ... formula, is now available in convenient,smaller-sized soft gels. ... same exceptionally high concentrated oil as Ultimate Omega, ... swallowing. Ideal for ages 5,through adult, the all ...
... FORT MYERS, Fla., Nov. 14 NeoGenomics, Inc.,(OTC Bulletin ... its results for the third quarter of FY 2007.,Significant ... nine,months of the year included the following: Third ... revenues in Q3 07 vs. Q3 06 -- ...
... Ill., Nov. 14 Delta Dental, the nation,s,largest ... Readers,Choice Award from Benefits Selling magazine as the ... and network availability. The,awards were announced in the ... Selling surveys its readers annually, asking them to ...
... reporting the first successful strategy to reduce smokers nicotine ... study provides strong support for proposals now being considered ... according to the research team. , The key to ... of gradually decreasing nicotine content over a number of ...
... 14 On the first United Nations World,Diabetes ... to develop national policies for the prevention, care ... to consider the need,for a diabetes global fund ... at the World Diabetes Day press conference, Dr ...
Cached Medicine News:Health News:Anthem Blue Cross and Blue Shield in Kentucky Announces Release of State Health Index 2Health News:Anthem Blue Cross and Blue Shield in Kentucky Announces Release of State Health Index 3Health News:Anthem Blue Cross and Blue Shield in Kentucky Announces Release of State Health Index 4Health News:Nordic Naturals Introduces Ultimate Omega 500 - Their Best Selling Formula Now Available in a Smaller Size Soft Gel! 2Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 2Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 3Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 4Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 5Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 6Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 7Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 8Health News:Brokers Name Delta Dental the Best in Coverage, Plan Design and Networks 2Health News:Nicotine addiction slashed in test of new cigarette smoking strategy 2Health News:Nicotine addiction slashed in test of new cigarette smoking strategy 3Health News:First United Nations World Diabetes Day Unites Global Diabetes Community to Fight the Epidemic 2Health News:First United Nations World Diabetes Day Unites Global Diabetes Community to Fight the Epidemic 3Health News:First United Nations World Diabetes Day Unites Global Diabetes Community to Fight the Epidemic 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: